HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.

Abstract
The origin of the epidemic of IgE-associated (allergic) diseases is unclear. MeDALL (Mechanisms of the Development of ALLergy), an FP7 European Union project (No. 264357), aims to generate novel knowledge on the mechanisms of initiation of allergy and to propose early diagnosis, prevention, and targets for therapy. A novel phenotype definition and an integrative translational approach are needed to understand how a network of molecular and environmental factors can lead to complex allergic diseases. A novel, stepwise, large-scale, and integrative approach will be led by a network of complementary experts in allergy, epidemiology, allergen biochemistry, immunology, molecular biology, epigenetics, functional genomics, bioinformatics, computational and systems biology. The following steps are proposed: (i) Identification of 'classical' and 'novel' phenotypes in existing birth cohorts; (ii) Building discovery of the relevant mechanisms in IgE-associated allergic diseases in existing longitudinal birth cohorts and Karelian children; (iii) Validation and redefinition of classical and novel phenotypes of IgE-associated allergic diseases; and (iv) Translational integration of systems biology outcomes into health care, including societal aspects. MeDALL will lead to: (i) A better understanding of allergic phenotypes, thus expanding current knowledge of the genomic and environmental determinants of allergic diseases in an integrative way; (ii) Novel diagnostic tools for the early diagnosis of allergy, targets for the development of novel treatment modalities, and prevention of allergic diseases; (iii) Improving the health of European citizens as well as increasing the competitiveness and boosting the innovative capacity of Europe, while addressing global health issues and ethical issues.
AuthorsJ Bousquet, J Anto, C Auffray, M Akdis, A Cambon-Thomsen, T Keil, T Haahtela, B N Lambrecht, D S Postma, J Sunyer, R Valenta, C A Akdis, I Annesi-Maesano, A Arno, C Bachert, F Ballester, X Basagana, U Baumgartner, C Bindslev-Jensen, B Brunekreef, K H Carlsen, L Chatzi, R Crameri, E Eveno, F Forastiere, J Garcia-Aymerich, S Guerra, H Hammad, J Heinrich, D Hirsch, B Jacquemin, F Kauffmann, M Kerkhof, M Kogevinas, G H Koppelman, M L Kowalski, S Lau, K C Lodrup-Carlsen, M Lopez-Botet, J Lotvall, C Lupinek, D Maier, M J Makela, F D Martinez, J Mestres, I Momas, M C Nawijn, A Neubauer, S Oddie, S Palkonen, I Pin, C Pison, F Rancé, S Reitamo, E Rial-Sebbag, M Salapatas, V Siroux, D Smagghe, M Torrent, E Toskala, P van Cauwenberge, A J M van Oosterhout, R Varraso, L von Hertzen, M Wickman, C Wijmenga, M Worm, J Wright, T Zuberbier
JournalAllergy (Allergy) Vol. 66 Issue 5 Pg. 596-604 (May 2011) ISSN: 1398-9995 [Electronic] Denmark
PMID21261657 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2011 John Wiley & Sons A/S.
Topics
  • Cooperative Behavior
  • European Union
  • Humans
  • Hypersensitivity (diagnosis, drug therapy, etiology, prevention & control)
  • Medication Systems
  • Phenotype
  • Systems Biology

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: